Bicara Therapeutics (NASDAQ:BCAX) Research Coverage Started at TD Cowen

TD Cowen started coverage on shares of Bicara Therapeutics (NASDAQ:BCAX) in a research note released on Tuesday morning, MarketBeat.com reports. The firm issued a buy rating on the stock.

Separately, Stifel Nicolaus assumed coverage on Bicara Therapeutics in a research report on Tuesday. They set a buy rating and a $47.00 price objective for the company.

Bicara Therapeutics Trading Down 6.4 %

Shares of BCAX stock opened at $19.00 on Tuesday. Bicara Therapeutics has a 12-month low of $18.58 and a 12-month high of $27.94.

Insiders Place Their Bets

In other news, major shareholder James E. Flynn purchased 70,000 shares of the stock in a transaction on Tuesday, September 17th. The shares were acquired at an average price of $18.00 per share, with a total value of $1,260,000.00. Following the completion of the acquisition, the insider now directly owns 897,587 shares of the company’s stock, valued at $16,156,566. This trade represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. In related news, Director Ra Capital Management, L.P. purchased 1,833,000 shares of the firm’s stock in a transaction on Monday, September 16th. The shares were acquired at an average price of $18.00 per share, for a total transaction of $32,994,000.00. Following the purchase, the director now directly owns 4,303,418 shares in the company, valued at $77,461,524. This trade represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder James E. Flynn purchased 70,000 shares of the business’s stock in a transaction on Tuesday, September 17th. The shares were purchased at an average price of $18.00 per share, with a total value of $1,260,000.00. Following the acquisition, the insider now directly owns 897,587 shares in the company, valued at $16,156,566. This represents a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here.

About Bicara Therapeutics

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.